Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

Abstract

Octreotide may influence the natural history of neuroendocrine tumors. The survival in patients treated with octreotide, as measured from the time of progression of disease, compares favorably with that of historical controls. Proof of a survival advantage for patients treated with octreotide would require a multicenter, randomized trial.